The DO-IT Study

https://www.uwactu.com/the-do-it-study

We want to understand why some people gain excessive weight while taking HIV treatment, and whether switching the HIV treatment regimen can help. Body weight can change throughout our lifetime and is influenced by multiple factors. Previous studies showed that people living with HIV may gain more weight when taking an integrase inhibitor, especially with tenofovir alafenamide (TAF). When compared to other regimens, these studies also showed that women and African Americans were disproportionately impacted by weight changes while on HIV treatment with integrase inhibitors. The DO IT study will answer these important questions for individuals who have gained substantial weight while taking an integrase inhibitor (bictegravir [BIC], dolutegravir [DTG], or raltegravir [RAL]) with TAF. It is designed to compare weight change for those who either stay with their current regimen or switch to a regimen with doravirine (DOR). There will be three groups: Group 1: DOR + TAF/FTC, Group 2: DOR + TDF/FTC, Group 3: will continue on their current treatment regimen

Participant Eligibility

People living with HIV

Ages 18 and older

Overweight (BMI > 27.5 kg/m2) and excessive weight gain (>10%) over the past 1-3 years

Currently on HIV treatment including BIC, DTG, or RAL and TAF regimen for at least 48 weeks:

If you started one of these integrase inhibitors and TAF at different times, you should be on TAF for at least 48 weeks

If you began TAF w/another integrase inhibitor, you should be on a BIC, DTG, or RAL-containing regimen for at least 24 weeks.

HIV viral load of 50 or less

Contact

Eli Burnham, PA-C
(206) 773-7129